Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Heart Test Laboratories Inc HSCS

Healthcare Medical Devices
Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Company’s initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the... see more

Recent & Breaking News (NDAQ:HSCS)

HeartSciences to Present at the LD Micro Invitational XIV Conference

GlobeNewswire April 2, 2024

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

GlobeNewswire March 26, 2024

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

GlobeNewswire March 14, 2024

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

GlobeNewswire March 12, 2024

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

GlobeNewswire March 6, 2024

HeartSciences Adds Key Advisor to its Scientific Advisory Board

GlobeNewswire February 26, 2024

HeartSciences Expands its Scientific Advisory Board

GlobeNewswire February 12, 2024

HeartSciences Appoints New Scientific Advisory Board Member

GlobeNewswire February 1, 2024

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

GlobeNewswire January 18, 2024

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

GlobeNewswire January 3, 2024

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

GlobeNewswire December 14, 2023

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

GlobeNewswire December 5, 2023

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

GlobeNewswire November 20, 2023

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

GlobeNewswire November 13, 2023

HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

GlobeNewswire October 19, 2023

HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio

GlobeNewswire September 26, 2023

HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.

GlobeNewswire September 25, 2023

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

GlobeNewswire September 21, 2023

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

GlobeNewswire September 14, 2023

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

GlobeNewswire September 12, 2023